We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current IMRX market cap is 64.58M. The company's latest EPS is USD -1.7221 and P/E is -1.25.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -13.93M | -16.3M | -15.33M | -14.91M | -15.27M |
| Net Income | -12.6M | -15.08M | -14.31M | -14.08M | -14.6M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 1.92M | 2.31M | 2.08M | 317k | 0 |
| Operating Income | -6.29M | -17.08M | -33.89M | -51.75M | -58.41M |
| Net Income | -7.71M | -17.04M | -33.54M | -50.51M | -53.47M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 113.88M | 102.59M | 87.98M | 77.09M | 68.56M |
| Total Liabilities | 9.86M | 12.01M | 9.26M | 10.78M | 10.84M |
| Total Equity | 104.02M | 90.58M | 78.72M | 66.31M | 57.72M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 14.1M | 38.42M | 166.71M | 122.37M | 102.59M |
| Total Liabilities | 4.02M | 2.8M | 10.73M | 12.52M | 12.01M |
| Total Equity | -6.53M | -22.48M | 155.98M | 109.85M | 90.58M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -37.19M | -48.97M | -15.49M | -27.02M | -40.49M |
| Investing | 4.16M | 7.3M | 21.39M | 26.36M | 20.94M |
| Financing | 28.43M | 28.44M | 979k | 979k | 5.35M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -4.44M | -14.62M | -30.85M | -44.1M | -48.97M |
| Investing | -21k | -53k | -75.62M | 41.83M | 7.3M |
| Financing | 17.17M | 37.98M | 144.27M | 19k | 28.44M |
| Market Cap | 64.58M |
| Price to Earnings Ratio | -1.25 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 1.12 |
| Price to Book Ratio | 0.74 |
| Dividend Yield | - |
| Shares Outstanding | 31.05M |
| Average Volume (1 week) | 551.15k |
| Average Volume (1 Month) | 5.96M |
| 52 Week Change | -65.39% |
| 52 Week High | 7.68 |
| 52 Week Low | 1.00 |
| Spread (Intraday) | 0.17 (7.91%) |
| Company Name | Immuneering Corporation |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://www.immuneering.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
